# UroGen Pharma to Present at Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-upcoming-investor-conferences
Ticker: URGN
Company: UroGen Pharma
Source: UroGen Pharma
Published: 2026-05-07 12:00 EST
Original Source URL: https://investors.urogen.com
## Summary

PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in May.

## Article Body
PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in May.
## Recent Company News
- 2026-06-02 12:00 EST — [UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution](https://biopharmsignal.com/news/URGN/urogen-announces-agreement-resolving-patent-litigation-relating-to-jelmytor-mitomycin-for-pyelocalyceal-solution) — Source: UroGen Pharma
- 2026-06-01 20:10 EST — [UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: UroGen Pharma
- 2026-05-15 12:00 EST — [UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC](https://biopharmsignal.com/news/URGN/urogen-reports-94-5-six-month-duration-of-response-in-phase-3-utopia-trial-advancing-ugn-103-toward-potential-approval-in-recurrent-low-grade-intermediate-risk-nmibc) — Source: UroGen Pharma
- 2026-05-13 12:00 EST — [ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial](https://biopharmsignal.com/news/URGN/zusduri-median-duration-of-response-still-not-reached-with-64-5-36-month-duration-of-response-in-the-pivotal-envision-trial) — Source: UroGen Pharma
- 2026-05-07 12:00 EST — [UroGen Pharma to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-upcoming-investor-conferences) — Source: UroGen Pharma
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)